Compare HSBC Holdings plc (HSBC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Illumina, Inc. — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: HSBC Holdings plc is far larger — about 7.8× Illumina, Inc.'s market cap, and HSBC Holdings plc pays a 4.05% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Illumina, Inc. for 83 Days on average.
| HSBC | ILMN | |
|---|---|---|
Market Cap | $311.92B | $39.95B |
Volume | 3,546,658 | 3,169,503 |
Sector | Financials | Health |
52-Week High | $107.86 | $293.69 |
52-Week Low | $65.67 | $91.00 |
Typical Hold Time | 36 Days | 83 Days |
Enterprise Value | $222.19B | $41.31B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
